Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK – A16037)

BACKGROUND: Recurrent epithelial ovarian cancer (EOC) remains difficult to treat, with an urgent need for more therapy options. Androgens bind to the androgen receptor (AR), commonly expressed in EOC. CYP17 inhibitor abiraterone irreversibly inhibits androgen biosynthesis. The Cancer of the Ovary Ab...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ther Adv Med Oncol
Autors principals: Banerjee, Susana, Tovey, Holly, Bowen, Rebecca, Folkerd, Elizabeth, Kilburn, Lucy, McLachlan, Jennifer, Hall, Marcia, Tunariu, Nina, Attygalle, Ayoma, Lima, Joao Paulo Da Silveira Nogueira, Perry, Sophie, Chatfield, Peter, Hills, Margaret, Kaye, Stan, Attard, Gert, Dowsett, Mitch, Bliss, Judith M.
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8013695/
https://ncbi.nlm.nih.gov/pubmed/33854564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920975352
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars